Alexion Pharma (ALXN) Says Data from Global aHUS Registry Shows Reduced Risk with Soliris
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating SolirisĀ® (eculizumab) Treatment Prior to Transplant Compared to
November 17, 2016 5:32 PM EST- Reduction in Incidence of Chronic Dialysis was also Observed in Patients Initiating Soliris Treatment Prior to Transplant -
- Reduction in Dialysis was Sustained Post-Transplant with Ongoing Treatment -
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that researchers presented new data from an analysis of patients enrolled in the Global atypical Hemolytic Uremic Syndrome (aHUS) Registry, demonstrating that initiation of Soliris® (eculizumab) prior to kidney transplant reduces the risk of dialysis post-transplant in patients with aHUS. Specifically, results showed that starting... More